Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay J Mathew

Showing results (111-120 of 190) with videos related to

Pageof 19
Sort By:
Journal of Clinical Psychopharmacology|May 12, 2015
Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind StudiesZubin Bhagwagar, Anne Torbeyns, Delphine Hennicken, et al.
Biological Psychiatry|March 8, 2011
Tryptophan depletion and emotional processing in healthy volunteers at high risk for depressionAdriana Feder, Jamie Skipper, James R Blair, et al.
Frontiers in Psychiatry|January 11, 2020
A Proof-of-Mechanism Study to Test Effects of the NMDA Receptor Antagonist Lanicemine on Behavioral Sensitization in Individuals With Symptoms of PTSDMarijn Lijffijt, Charles E Green, Nicholas Balderston, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|April 7, 2021
Does mismatch negativity have utility for NMDA receptor drug development in depression?Nicholas Murphy, Marijn Lijffijt, Nithya Ramakrishnan, et al.
Psychiatry Research|December 8, 2023
Anti-suicidal effects of IV ketamine in a real-world settingBrittany O'Brien, Jaehoon Lee, Seungman Kim, et al.
Psychiatry Research|June 27, 2006
Decreased choline and creatine concentrations in centrum semiovale in patients with generalized anxiety disorder: relationship to IQ and early traumaJeremy D Coplan, Sanjay J Mathew, Xiangling Mao, et al.
Stress (Amsterdam, Netherlands)|August 21, 2002
Cerebrospinal fluid concentrations of biogenic amines and corticotropin-releasing factor in adolescent non-human primates as a function of the timing of adverse early rearingSanjay J Mathew, Jeremy D Coplan, Eric L P Smith, et al.
Brain, Behavior, and Immunity|April 6, 2025
Lack of relationships between ketamine treatment and peripheral neurotrophic and inflammatory factors in a randomized controlled ketamine trial of major depressive disorderManivel Rengasamy, Benjamin Panny, Zakary Hutchinson, et al.
Journal of Clinical Psychopharmacology|April 26, 2020
Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive DisorderMarlene P Freeman, Rebecca S Hock, George I Papakostas, et al.
Biological Psychiatry|March 6, 2025
Effects of the KCNQ (Kv7) Channel Opener Ezogabine on Resting-State Functional Connectivity of Striatal Brain Reward Regions, Depression, and Anhedonia in Major Depressive Disorder: Results From a Randomized Controlled TrialAvijit Chowdhury, Sarah Boukezzi, Sara Costi, et al.
Pageof 19

Showing results (111-120 of 190) with videos related to

Sort By:
Pageof 19
Journal of Clinical Psychopharmacology|May 12, 2015
Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind StudiesZubin Bhagwagar, Anne Torbeyns, Delphine Hennicken, et al.
Biological Psychiatry|March 8, 2011
Tryptophan depletion and emotional processing in healthy volunteers at high risk for depressionAdriana Feder, Jamie Skipper, James R Blair, et al.
Frontiers in Psychiatry|January 11, 2020
A Proof-of-Mechanism Study to Test Effects of the NMDA Receptor Antagonist Lanicemine on Behavioral Sensitization in Individuals With Symptoms of PTSDMarijn Lijffijt, Charles E Green, Nicholas Balderston, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|April 7, 2021
Does mismatch negativity have utility for NMDA receptor drug development in depression?Nicholas Murphy, Marijn Lijffijt, Nithya Ramakrishnan, et al.
Psychiatry Research|December 8, 2023
Anti-suicidal effects of IV ketamine in a real-world settingBrittany O'Brien, Jaehoon Lee, Seungman Kim, et al.
Psychiatry Research|June 27, 2006
Decreased choline and creatine concentrations in centrum semiovale in patients with generalized anxiety disorder: relationship to IQ and early traumaJeremy D Coplan, Sanjay J Mathew, Xiangling Mao, et al.
Stress (Amsterdam, Netherlands)|August 21, 2002
Cerebrospinal fluid concentrations of biogenic amines and corticotropin-releasing factor in adolescent non-human primates as a function of the timing of adverse early rearingSanjay J Mathew, Jeremy D Coplan, Eric L P Smith, et al.
Brain, Behavior, and Immunity|April 6, 2025
Lack of relationships between ketamine treatment and peripheral neurotrophic and inflammatory factors in a randomized controlled ketamine trial of major depressive disorderManivel Rengasamy, Benjamin Panny, Zakary Hutchinson, et al.
Journal of Clinical Psychopharmacology|April 26, 2020
Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive DisorderMarlene P Freeman, Rebecca S Hock, George I Papakostas, et al.
Biological Psychiatry|March 6, 2025
Effects of the KCNQ (Kv7) Channel Opener Ezogabine on Resting-State Functional Connectivity of Striatal Brain Reward Regions, Depression, and Anhedonia in Major Depressive Disorder: Results From a Randomized Controlled TrialAvijit Chowdhury, Sarah Boukezzi, Sara Costi, et al.
Pageof 19